Valneva

About:

Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.

Website: http://www.valneva.com

Twitter/X: valnevase

Top Investors: Pfizer, Bpifrance, OrbiMed, Deerfield, Deep Track Capital

Description:

Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19.

Total Funding Amount:

$854M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Saint-herblain, Pays de la Loire, France

Founded Date:

2013-01-01

Contact Email:

bd(AT)valneva.com

Founders:

Number of Employees:

501-1000

Last Funding Date:

2024-09-13

IPO Status:

Public

© 2025 bioDAO.ai